RU2013116373A - Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер - Google Patents

Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер Download PDF

Info

Publication number
RU2013116373A
RU2013116373A RU2013116373/15A RU2013116373A RU2013116373A RU 2013116373 A RU2013116373 A RU 2013116373A RU 2013116373/15 A RU2013116373/15 A RU 2013116373/15A RU 2013116373 A RU2013116373 A RU 2013116373A RU 2013116373 A RU2013116373 A RU 2013116373A
Authority
RU
Russia
Prior art keywords
mhc
cells
complex
biocompatible
nanosphere
Prior art date
Application number
RU2013116373/15A
Other languages
English (en)
Other versions
RU2635537C2 (ru
Inventor
Педро САНТАМАРИЯ
Original Assignee
Ютиай Лимитед Партнершип
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ютиай Лимитед Партнершип filed Critical Ютиай Лимитед Партнершип
Publication of RU2013116373A publication Critical patent/RU2013116373A/ru
Application granted granted Critical
Publication of RU2635537C2 publication Critical patent/RU2635537C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6923—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being an inorganic particle, e.g. ceramic particles, silica particles, ferrite or synsorb
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
    • A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
    • A61K47/6937—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol the polymer being PLGA, PLA or polyglycolic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Nanotechnology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Ceramic Engineering (AREA)
  • Endocrinology (AREA)

Abstract

1. Способ диагностики, предупреждения или лечения аутоиммунного нарушения, включающий введение субъекту комплекса антиген-МНС, функционально связанного с биологически совместимой биоабсорбируемой наносферой в количестве, достаточном для пролиферации антипатогенных аутореактивных Т клеток.2. Способ увеличения и/или развития популяций антипатогенных аутореактивных Т-клеток у субъекта, включающий введение этому субъекту комплекса аутоантигенный эпитоп-МНС-биологически совместимая биодеградируемая наносфера, в котором указанный комплекс вводят в количестве и с частотой, достаточных для увеличения указанных популяций.3. Способ по п.2, в котором в составе указанного комплекса аутоантигенный эпитоп-МНС биологически совместимая биоадеградируемая наносфера содержится множество аутоантигенных эпитопов.4. Способ по п.3, в котором указанное множество аутоантигенных эпитопов являются производными единственного аутоантигена.5. Способ по п.3, в котором указанное множество аутоантигенных эпитопов являются производными множества аутоантигенов.6. Способ по п.5, в котором увеличение популяции антипатогенных аутореактивных Т-клеток является антиген-специфичным, но клетки обладают антиген-неспецифичным характером супрессии.7. Способ по любому из пп.2, 4 или 5, в котором введение указанного комплекса биологически совместимых абсорбируемых наносфер вызывает деплецию популяции родственных патогенных аутореактивных Т-клеток.8. Способ по любому из пп.2, 4 или 5, в котором введение указанного комплекса биологически совместимых абсорбируемых наносфер вызывает деплецию популяции неродственных патогенных аутореактивных Т-к

Claims (22)

1. Способ диагностики, предупреждения или лечения аутоиммунного нарушения, включающий введение субъекту комплекса антиген-МНС, функционально связанного с биологически совместимой биоабсорбируемой наносферой в количестве, достаточном для пролиферации антипатогенных аутореактивных Т клеток.
2. Способ увеличения и/или развития популяций антипатогенных аутореактивных Т-клеток у субъекта, включающий введение этому субъекту комплекса аутоантигенный эпитоп-МНС-биологически совместимая биодеградируемая наносфера, в котором указанный комплекс вводят в количестве и с частотой, достаточных для увеличения указанных популяций.
3. Способ по п.2, в котором в составе указанного комплекса аутоантигенный эпитоп-МНС биологически совместимая биоадеградируемая наносфера содержится множество аутоантигенных эпитопов.
4. Способ по п.3, в котором указанное множество аутоантигенных эпитопов являются производными единственного аутоантигена.
5. Способ по п.3, в котором указанное множество аутоантигенных эпитопов являются производными множества аутоантигенов.
6. Способ по п.5, в котором увеличение популяции антипатогенных аутореактивных Т-клеток является антиген-специфичным, но клетки обладают антиген-неспецифичным характером супрессии.
7. Способ по любому из пп.2, 4 или 5, в котором введение указанного комплекса биологически совместимых абсорбируемых наносфер вызывает деплецию популяции родственных патогенных аутореактивных Т-клеток.
8. Способ по любому из пп.2, 4 или 5, в котором введение указанного комплекса биологически совместимых абсорбируемых наносфер вызывает деплецию популяции неродственных патогенных аутореактивных Т-клеток.
9. Комплекс аутоантигенный эпитоп-МНС-биологически совместимая биоабсорбируемая наносфера, содержащий биологически совместимое ядро и биодеградируемое покрытие на внешней поверхности указанного ядра.
10. Комплекс аутоантигенный эпитоп-МНС-биологически совместимая биоабсорбируемая наносфера по п.9, в котором указанное биологически совместимое ядро состоит из оксида железа (III).
11. Комплекс аутоантигенный эпитоп-МНС-биологически совместимая биоабсорбируемая наносфера по п.9, в котором указанное биологически совместимое покрытие выбрано из декстрана, маннита и поли(этиленгликоля).
12. Комплекс аутоантигенный эпитоп-МНС-биологически совместимая биоабсорбируемая наносфера по п.9, в котором указанная наносфера ковалентно связана с группой МНС комплекса аутоантигенный эпитоп-МНС, в котором указанное связывание возможно осуществляется при помощи линкера.
13. Способ ингибирования начала аутоиммунного заболевания, в котором указанный способ включает введение субъекту комплекса антиген-МНС, функционально связанного с биологически совместимой наносферой, в количестве, достаточном для пролиферации антипатогенных аутореактивных Т-клеток, в котором молекула МНС содержит молекулы II класса МНС.
14. Способ по п.13, в котором указанные аутореактивные Т-клетки представляют собой CD4+ TR1 клетки.
15. Способ по п.14, в котором указанные CD4+ TR1 клетки характеризуются экспрессией IL-10 и IFNγ.
16. Способ лечения воспалительного компонента аутоиммунного заболевания, в котором указанный способ включает:
введение субъекту, страдающему аутоиммунным заболеванием, имеющим воспалительный компонент, комплекса антиген-МНС, функционально связанного с биологически совместимой наносферой, в котором молекула МНС включает молекулы II класса МНС, а указанный антиген специфичен в отношении аутоиммунного заболевания, и в котором указанное введение указанного комплекса осуществляется в количестве, достаточном для увеличения популяции антипатогенных аутореактивных TR1 клеток, экспрессирующих IL-10;
возможность накопления указанных TR1 клеток в очагах указанного аутоиммунного заболевания, за счет чего в указанных очагах накапливается IL-10, при условиях, приводящих к уменьшению воспалительного компонента аутоиммунного заболевания.
17. Способ по п.16, в котором молекула МНС представляет собой молекулу II класса МНС.
18. Способ по п.16, в котором указанные аутореактивные Т-клетки представляют собой CD4+ TR1 клетки.
19. Способ по п.18, в котором указанные CD4+ TR1 клетки характеризуются экспрессией IL-10 и IFNγ.
20. Способ по любому из пп.13 или 16, в котором указанная наносфера образована из одного или более биологически совместимых биоабсорбируемых материалов.
21. Способ лечения аутоиммунного заболевания у пациента путем введения комплексов антиген-МНС, функционально связанных с биологически совместимой наносферой пациенту в количестве, достаточном для пролиферации антипатогенных аутореактивных Т-клеток, в котором молекула МНС содержит как молекулы I класса МНС, так и молекулы II класса МНС.
22. Способ по п.21, в котором указанное аутоиммунное заболевание представляет собой сахарный диабет I типа.
RU2013116373A 2010-09-29 2011-09-29 Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер RU2635537C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38787310P 2010-09-29 2010-09-29
US61/387,873 2010-09-29
PCT/EP2011/066994 WO2012041968A1 (en) 2010-09-29 2011-09-29 Methods for treating autoimmune disease using biocompatible bioabsorbable nanospheres

Publications (2)

Publication Number Publication Date
RU2013116373A true RU2013116373A (ru) 2014-11-10
RU2635537C2 RU2635537C2 (ru) 2017-11-13

Family

ID=44764128

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2013116373A RU2635537C2 (ru) 2010-09-29 2011-09-29 Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер

Country Status (19)

Country Link
US (3) US20120093934A1 (ru)
EP (2) EP3308797A1 (ru)
JP (2) JP6106591B2 (ru)
KR (2) KR20130124487A (ru)
CN (2) CN105497883A (ru)
AU (2) AU2011310513C1 (ru)
BR (1) BR112013007069A2 (ru)
CA (1) CA2813064C (ru)
DK (1) DK2621523T3 (ru)
ES (1) ES2644865T3 (ru)
HU (1) HUE035000T2 (ru)
IL (1) IL225470A0 (ru)
MX (1) MX362653B (ru)
NZ (1) NZ608693A (ru)
PL (1) PL2621523T3 (ru)
PT (1) PT2621523T (ru)
RU (1) RU2635537C2 (ru)
SG (2) SG10201510366RA (ru)
WO (1) WO2012041968A1 (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US20140105980A1 (en) * 2012-10-11 2014-04-17 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
US9511151B2 (en) 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer
US10988516B2 (en) 2012-03-26 2021-04-27 Uti Limited Partnership Methods and compositions for treating inflammation
US9603948B2 (en) 2012-10-11 2017-03-28 Uti Limited Partnership Methods and compositions for treating multiple sclerosis and related disorders
CN103235135B (zh) * 2013-04-26 2015-02-04 史其新 一种用于表征外周调节性t细胞抑制活性的特征细胞群的检测方法及其应用
SG10201912301XA (en) 2013-11-04 2020-02-27 Uti Lp Methods and compositions for sustained immunotherapy
US12011480B2 (en) * 2015-05-06 2024-06-18 Uti Limited Partnership Nanoparticle compositions for sustained therapy
CA3056368A1 (en) * 2016-03-15 2017-09-21 Biomerica, Inc. Compositions, devices, and methods of fibromyalgia sensitivity testing
WO2017184592A1 (en) 2016-04-18 2017-10-26 University Of Maryland, College Park Harnessing quantum dots to study, visualize, and promote immune tolerance
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
AU2018374569B2 (en) * 2017-11-29 2024-10-17 Uti Limited Partnership Methods of treating autoimmune disease
CN110836966A (zh) * 2018-08-15 2020-02-25 王镕 用于抗原特异性t细胞含量检测的检测纳米颗粒、检测方法及试剂盒等
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
GB201913408D0 (en) * 2019-09-17 2019-10-30 King S College London Proinsulin peptides for type 1 diabetes
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4367110A (en) 1979-07-02 1983-01-04 Toppan Printing Co. Decorative laminate and a manufacturing method therefor
US4452901A (en) 1980-03-20 1984-06-05 Ciba-Geigy Corporation Electrophoretically transferring electropherograms to nitrocellulose sheets for immuno-assays
US4554101A (en) 1981-01-09 1985-11-19 New York Blood Center, Inc. Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
GB2097032B (en) 1981-04-22 1984-09-19 Teron International Urban Dev A combined ceiling air and services distribution system mechanical chasse and structural roof member
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3377484D1 (en) 1982-04-19 1988-09-01 Nissan Motor Method for controlling reduction ratio of continuously variable transmission with acceleration compensation
US4443508A (en) 1982-09-30 1984-04-17 Norfab, Inc. Edge protector
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
ATE66469T1 (de) 1985-01-14 1991-09-15 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
US6103379A (en) 1994-10-06 2000-08-15 Bar-Ilan University Process for the preparation of microspheres and microspheres made thereby
AU741130B2 (en) * 1997-09-16 2001-11-22 Oregon Health Sciences University Recombinant MHC molecules useful for manipulation of antigen-specific T-cells
AU3896699A (en) 1998-05-07 1999-11-23 Regents Of The University Of California, The Use of neglected target tissue antigens in modulation of immune responses
US6150022A (en) 1998-12-07 2000-11-21 Flex Products, Inc. Bright metal flake based pigments
US6651655B1 (en) 2000-01-18 2003-11-25 Quadrant Technologies Limited Inhaled vaccines
KR100379250B1 (ko) 2000-12-04 2003-04-08 한국과학기술연구원 나노 단위 크기의 금속 입자가 함유된 고분자 복합 소재및 그 제조 방법
EP1466015B1 (en) 2001-11-09 2008-08-06 Nanosphere, Inc. Bioconjugate-nanoparticle probes
US20070059775A1 (en) 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
WO2007024026A1 (ja) * 2005-08-25 2007-03-01 Taiho Pharmaceutical Co., Ltd. Ｔ細胞認識エピトープペプチドを固定化又は内包化した生分解性ナノ粒子
CN101678090B (zh) * 2007-03-07 2012-04-11 乌第有限合伙公司 用于预防和治疗自身免疫病的组合物和方法
US9511151B2 (en) * 2010-11-12 2016-12-06 Uti Limited Partnership Compositions and methods for the prevention and treatment of cancer

Also Published As

Publication number Publication date
MX362653B (es) 2019-01-30
EP2621523B1 (en) 2017-08-09
AU2011310513B2 (en) 2016-02-11
RU2635537C2 (ru) 2017-11-13
ES2644865T3 (es) 2017-11-30
US20120093934A1 (en) 2012-04-19
AU2016202944B2 (en) 2017-09-28
HUE035000T2 (en) 2018-03-28
AU2011310513A1 (en) 2013-04-11
JP6106591B2 (ja) 2017-04-05
MX2013003559A (es) 2013-09-02
AU2016202944A1 (en) 2016-06-09
EP3308797A1 (en) 2018-04-18
JP2013541532A (ja) 2013-11-14
EP2621523A1 (en) 2013-08-07
CN103237559A (zh) 2013-08-07
PT2621523T (pt) 2017-11-15
KR20130124487A (ko) 2013-11-14
KR101972291B1 (ko) 2019-08-16
KR20180088736A (ko) 2018-08-06
DK2621523T3 (da) 2017-11-20
PL2621523T3 (pl) 2018-04-30
JP2017114870A (ja) 2017-06-29
SG188653A1 (en) 2013-04-30
CN105497883A (zh) 2016-04-20
IL225470A0 (en) 2013-06-27
US20190134171A1 (en) 2019-05-09
AU2011310513C1 (en) 2016-06-02
CA2813064A1 (en) 2012-04-05
BR112013007069A2 (pt) 2016-09-13
NZ608693A (en) 2015-06-26
SG10201510366RA (en) 2016-01-28
US20230355730A1 (en) 2023-11-09
WO2012041968A1 (en) 2012-04-05
CA2813064C (en) 2021-06-01

Similar Documents

Publication Publication Date Title
RU2013116373A (ru) Способ лечения аутоиммунного заболевания с использованием биосовместимых биоабсорбируемых наносфер
Wu et al. An immune cocktail therapy to realize multiple boosting of the cancer-immunity cycle by combination of drug/gene delivery nanoparticles
Su et al. Mesenchymal stromal exosome–functionalized scaffolds induce innate and adaptive immunomodulatory responses toward tissue repair
Liu et al. Nanofibrous spongy microspheres to distinctly release miRNA and growth factors to enrich regulatory T cells and rescue periodontal bone loss
Han et al. Melatonin facilitates adipose‐derived mesenchymal stem cells to repair the murine infarcted heart via the SIRT1 signaling pathway
Liu et al. RAD51 mediates resistance of cancer stem cells to PARP inhibition in triple-negative breast cancer
Gibori et al. Amphiphilic nanocarrier-induced modulation of PLK1 and miR-34a leads to improved therapeutic response in pancreatic cancer
US8980907B2 (en) Dendrimer conjugates
JP2013541532A5 (ru)
Wong et al. Adipose-derived stem cell extracellular vesicles: a systematic review✰
Wang et al. A bilaminated decellularized scaffold for islet transplantation: Structure, properties and functions in diabetic mice
Do et al. Type of MRI contrast, tissue gadolinium, and fibrosis
RU2013121571A (ru) Композиции и способы профилактики и лечения злокачественных новообразований
US11590234B2 (en) Hyperbranched polymers and polyplexes and DNA or RNA delivery systems including the same
Li et al. Elastic Nanovaccine Enhances Dendritic Cell‐Mediated Tumor Immunotherapy
Lightner et al. Mesenchymal stem cell injections for the treatment of perianal Crohn’s disease: what we have accomplished and what we still need to do
JP2016530217A (ja) ポリマー−キレーター複合体
Magisson et al. Safety and function of a new pre-vascularized bioartificial pancreas in an allogeneic rat model
Shah et al. Optimizing PLG nanoparticle-peptide delivery platforms for transplantation tolerance using an allogeneic skin transplant model
Li et al. Exosome‐based targeted RNA delivery for immune tolerance induction in skin transplantation
JP2017523130A (ja) 視神経脊髄炎の治療に対する高可溶性アクアポリン−４細胞外ループペプチド免疫化
Elizondo et al. Pancreatic islets seeded in a novel bioscaffold forms an organoid to rescue insulin production and reverse hyperglycemia in models of type 1 diabetes
Pan et al. Nanotechnology's application in Type 1 diabetes
Zhou et al. CX3CR1hi macrophages sustain metabolic adaptation by relieving adipose-derived stem cell senescence in visceral adipose tissue
Srakaew et al. Sodium-phosphorylated chitosan/zinc oxide complexes and evaluation of their cytocompatibility: An approach for periodontal dressing

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20200930